Profound Medical (PROF) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $2.83 million, up 64% year-over-year, driven by strong recurring revenue and a one-time equipment sale.

• Net loss widened to $9.4 million ($0.38/share) from $5.6 million ($0.26/share) in Q3 2023, reflecting higher operating expenses.

• Transition underway from a recurring revenue model to a traditional medical device model with capital sales, consumables, and service contracts, following favorable reimbursement changes.

• TULSA-PRO® installed base reached 59 systems; positive CMS reimbursement ruling expected to drive broader adoption.

• CAPTAIN trial enrollment on track to complete by year-end, with interim data expected in H1 2025.

Financial highlights

• Q3 2024 revenue: $2.83 million (up 64% from $1.73 million in Q3 2023); $2.65 million from recurring revenue, $179,000 from capital equipment sales.

• Gross margin improved to 64% from 61% in Q3 2023, with expectations to maintain or exceed 60% for the full year.

• Operating expenses rose 42% year-over-year to $10.8 million, with R&D up 22%, G&A up 84%, and sales/distribution up 34%.

• Net finance expense was $199,000, compared to net finance income of $1 million in Q3 2023.

• Cash at September 30, 2024 was $27.1 million.

Outlook and guidance

• Full-year 2024 revenue guidance reaffirmed at $11–$12 million, representing 53% to 67% year-over-year growth.

• Gross margin expected to remain at or above 60% for 2024.

• Utilization and installed base expected to grow, with a target of 75 installs soon after year-end.

• Anticipates a 30% capital/70% recurring revenue mix in the long term.